Genelabs deal

GNLB exclusively licensed from Stanford University DHEA dehydroepiandrosterone, a steriod hormone, to treat systemic lupus erythematosus. Stanford will receive milestones and royalties on sales.

Irene Chow, president of the company's pharma division, said GNLB licensed the compound because the company was looking for a product that could be rapidly commercialized. The company had been looking to in-license a product for a severe disease with no treatment. GNLB is hoping to file an IND by the end of the year for a Phase II/III trial. ...